Aug 16th 2012 - Edison Investment Research today published a report on Agennix entitled "Seeking A Way Forward". In summary, the report says:
Agennix’s Phase III FORTIS-M trial in non-small cell lung cancer (NSCLC) failed to demonstrate that talactoferrin as monotherapy provided any survival benefit over placebo. The company has initiated a restructuring programme to reduce cash burn. A strategic review is also under way to assess the potential of all of its assets. These include talactoferrin in NSCLC with chemotherapy (probably terminating FORTIS-C early), talactoferrin for nosocomial infections and RGB-286638 for tumours.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »